AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia

Leukemia. 2007 Oct;21(10):2199-201. doi: 10.1038/sj.leu.2404830. Epub 2007 Jul 12.

Authors

F Schneider, S K Bohlander, S Schneider, C Papadaki, P Kakadyia, A Dufour, S Vempati, M Unterhalt, M Feuring-Buske, C Buske, J Braess, H Wandt, W Hiddemann, K Spiekermann

PMID: 17625612
DOI: 10.1038/sj.leu.2404830

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Core Binding Factor Alpha 2 Subunit / physiology*
Cytoplasm / metabolism
DNA-Binding Proteins / physiology*
Disease Progression
Female
Gene Expression Regulation, Leukemic*
Humans
In Situ Hybridization, Fluorescence
Janus Kinase 2 / physiology*
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myeloid, Acute / metabolism
Leukemia, Myeloid, Acute / pathology*
Middle Aged
Models, Genetic
Mutation
Myeloproliferative Disorders / metabolism
Myeloproliferative Disorders / pathology*
Proto-Oncogene Proteins / physiology*
RUNX1 Translocation Partner 1 Protein
Transcription Factors / metabolism
Transcription Factors / physiology*

Substances

Core Binding Factor Alpha 2 Subunit
DNA-Binding Proteins
Proto-Oncogene Proteins
RUNX1 Translocation Partner 1 Protein
RUNX1 protein, human
RUNX1T1 protein, human
Transcription Factors
JAK2 protein, human
Janus Kinase 2